Search Result

Results for "

human lung adenocarcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) ADC Payload (2) Akt (1) Amino Acid Derivatives (1) AMPK (1) Antibiotic (2) Apoptosis (16) Arp2/3 Complex (1) Autophagy (1) Bacterial (3) Bcl-2 Family (1) Biochemical Assay Reagents (5) Calmodulin (1) Caspase (3) CD276/B7-H3 (1) Choline Kinase (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (3) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (1) E-Selectin (1) EGFR (3) Endogenous Metabolite (1) ERK (1) Fungal (1) Galectin (2) Glutathione Peroxidase (1) Integrin (1) Interleukin Related (2) LIM Kinase (LIMK) (1) Liposome (1) Lipoxygenase (1) MAP4K (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) MMP (1) MOFs (1) NAMPT (1) Neurotensin Receptor (1) NF-κB (1) NO Synthase (1) Oxidative Phosphorylation (1) p38 MAPK (1) PAK (1) Parasite (1) PARP (2) PD-1/PD-L1 (1) PDGFR (1) PDK-1 (1) PERK (1) PI3K (1) PROTACs (1) Pyroptosis (1) Pyruvate Kinase (1) Radionuclide-Drug Conjugates (RDCs) (1) Ras (2) Reactive Oxygen Species (ROS) (4) RET (1) Sirtuin (1) SOD (1) STAT (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Topoisomerase (2) Transmembrane Glycoprotein (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (52) Cardiovascular Disease (1) Endocrinology (1) Infection (6) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	CpG ODNs (1) Cationic Lipids (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114409

GB1107 Maximum Cited Publications 19 Publications Verification	Galectin	Cancer
GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a K_d of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model .

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909	Toll-like Receptor (TLR) Bacterial NO Synthase Apoptosis	Infection Cancer
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC₅₀ of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-124745

KY-05009 1 Publications Verification	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .

HY-W075517

ZIF-8 2-Methylimidazole zinc salt	Caspase Pyroptosis MOFs	Cancer
ZIF-8 (2-Methylimidazole zinc salt) is a caspase-1/Gasdermin D activator and a pH- and stimulus-responsive inducer of drug release, which serves as a highly efficient drug delivery carrier. ZIF-8 is a metal-organic framework (MOF). ZIF-8 activates the caspase-1/Gasdermin D-dependent pyroptosis pathway, induces pyroptosis, necrosis and immunogenic cell death, initiates in situ anti-tumor immunity, reprograms the immunosuppressive tumor microenvironment and inhibits tumor proliferation. ZIF-8 is applicable to related research on multiple cancers including colorectal cancer and breast cancer .

HY-Y0030

3-Hydroxypicolinic acid 3-hydroxypyridine-2-carboxylic acid	Biochemical Assay Reagents Drug Intermediate	Infection Cancer
3-Hydroxypicolinic acid is a heterocyclic carboxylic acid ligand and cytotoxin, with a MIC₉₀ of >25 μg/mL against Mycobacterium tuberculosis H37Rv. 3-Hydroxypicolinic acid inhibits the growth of cancer cells and normal fibroblasts. 3-Hydroxypicolinic acid is applicable to research related to chronic myeloid leukemia, human lung adenocarcinoma, and tuberculosis .

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-W020955

Triphenylphosphinechlorogold Chloro(triphenylphosphine)gold(I)	Biochemical Assay Reagents Apoptosis DNA Alkylator/Crosslinker Lipoxygenase	Cancer
Triphenylphosphinechlorogold (Chloro(triphenylphosphine)gold(I)) is a gold complex, Apoptosis inducer, and catalyst. Triphenylphosphinechlorogold exhibits high LOX inhibitory activity. Triphenylphosphinechlorogold induces cell cycle arrest and apoptosis. Triphenylphosphinechlorogold catalyzes the peroxidation of linoleic acid. A weak interaction exists between Triphenylphosphinechlorogold and DNA. Triphenylphosphinechlorogold displays antiproliferative activity against breast cancer cells .

HY-148819A

NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride	ADC Payload Topoisomerase	Cancer
NH2-bicyclopentane-7-MAD-MDCPT hydrochloride (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is used in research on lung adenocarcinoma and melanoma .

HY-N3225

Myricanol	NAMPT Sirtuin Microtubule/Tubulin Apoptosis Autophagy PDGFR NF-κB AMPK	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation .

HY-142997

DOSPA	Liposome	Cancer
DOSPA is a cationic lipid. DOSPA can form lipid nanoparticles with DOPE (HY-112005) to serve as a carrier for nucleic acid transfection. DOSPA is applicable in research related to drug delivery .

HY-N1745A

3-Deoxysappanchalcone 2 Publications Verification	Reactive Oxygen Species (ROS) Apoptosis	Infection Inflammation/Immunology Cancer
3-Deoxysappanchalcone is a natural chalcone compound isolated from the heartwood of Caesalpinia sappan L. 3-Deoxysappanchalcone induces cell cycle arrest, ROS production, and apoptosis. 3-Deoxysappanchalcone exhibits anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic activities. 3-Deoxysappanchalcone is applicable to research related to lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infection .

HY-16261A

MC-DOXHZN (E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone	ADC Payload Topoisomerase	Cancer
MC-DOXHZN ((E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone) is an albumin-binding proagent of Doxorubicin (HY-15142A) (DNA topoisomerase II inhibitor), with acid-sensitive properties. MC-DOXHZN can be used to synthesize ADC .

HY-165245

SBI-183	Transmembrane Glycoprotein	Cancer
SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .

HY-147027

PARP-1-IN-2	PARP Caspase Apoptosis	Neurological Disease Inflammation/Immunology Cancer
PARP-1-IN-2 (compound 11g) is a potent PARP1 inhibitor, with an IC₅₀ of 149 nM, and ADME prediction indicates it has high blood-brain barrier permeability. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .

HY-P991739

RC148	VEGFR PD-1/PD-L1	Cancer
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .

HY-N8420

Thalifoline	Fungal	Infection Cancer
Thalifoline is an isoquinoline alkaloid. Thalifoline exerts cytotoxic effects on cancer cells. Thalifoline inhibits the growth of Fusarium oxysporum f. sp. lycopersici. Thalifoline can be used in research related to lung adenocarcinoma, colon cancer, oral epidermoid carcinoma, and fungal infections .

HY-19015

Probimane AT-2153	Calmodulin	Cancer
Probimane (AT-2153) is a potent anticancer agent. Probimane is effective against mouse tumors S37, S180, Lewis lung carcinoma, L1210 and human pulmonary adenocarcinoma heterotransplanted into nude mice .

HY-16676

7-Epi-docetaxel 4-epi-Docetaxel; 7-Epidocetaxel; 7-Epitaxotere	Drug Metabolite Cytochrome P450	Cancer
7-Epi-docetaxel (4-epi-Docetaxel; 7-Epidocetaxel; 7-Epitaxotere) is the major C7 epimeric impurity/in vivo metabolite of Docetaxel (HY-B0011). 7-Epi-docetaxel acts as a potent allosteric activator of rhCYP1B1. 7-Epi-docetaxel exhibits certain cell line-specific anti-migratory activity . 7-Epi-docetaxel can be used in research related to melanoma and lung adenocarcinoma .

HY-W854385A

Sialyl Lewis A sodium 1 Publications Verification SLeA sodium	Biochemical Assay Reagents	Cancer
Sialyl Lewis A (SLeA) sodium is a tumor-associated carbohydrate antigen, also known as carbohydrate antigen 19-9 (CA19-9), that binds to E-selectin (ELAM-1) and selectins to mediate cell-endothelium adhesion. Sialyl Lewis A sodium promotes cancer cell-vascular endothelium adhesion, and its surface presence correlates with increased tumorigenicity and invasiveness in cancer cells. Sialyl Lewis A sodium shows elevated expression in human adenocarcinomas of the colon, pancreas, and stomach, with expression levels linked to tumor progression and poor prognosis in colorectal and gastric carcinomas. Sialyl Lewis A sodium can be used for the research of cancers, such as colon, pancreas, stomach, and squamous lung cancer .

HY-W854385

Sialyl Lewis A SLeA	Biochemical Assay Reagents E-Selectin	Cancer
Sialyl Lewis A (SLeA) is a tumor-associated carbohydrate antigen, also known as carbohydrate antigen 19-9 (CA19-9), that binds to E-selectin (ELAM-1) and selectins to mediate cell-endothelium adhesion. Sialyl Lewis A promotes cancer cell-vascular endothelium adhesion, and its surface presence correlates with increased tumorigenicity and invasiveness in cancer cells. Sialyl Lewis A shows elevated expression in human adenocarcinomas of the colon, pancreas, and stomach, with expression levels linked to tumor progression and poor prognosis in colorectal and gastric carcinomas. Sialyl Lewis A can be used for the research of cancers, such as colon, pancreas, stomach, and squamous lung cancer .

HY-162721

Anticancer agent 242	Biochemical Assay Reagents	Cancer
Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC₅₀ = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC₅₀ = 0.45 μM, resistant derivative of A2780), CCD18Co (IC₅₀ = 0.59 μM, non-malignant human fibroblasts), A549 (IC₅₀ = 0.32 μM, lung carcinoma), HT29 (IC₅₀ = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC₅₀ = 0.55 μM, breast adenocarcinoma) .

HY-N14303

16-Methyloxazolomycin	Antibiotic Bacterial	Infection Cancer
16-Methyloxazolomycin is an antibiotic. 16-Methyloxazolomycin has the effect of resisting bacteria and algae. 16-Methyloxazolomycin against leukemia P388 and human lung adenocarcinoma cells .

HY-N10363

Pixinol	Others	Cancer
Pixinol, a natural glycoside, shows cytotoxicity against the human lung carcinoma GLC4 and adenocarcinoma COLO 320 cell lines (IC₅₀=71 µM and 43 µM, respectively) .

HY-111320

Chrysomycin B	Bacterial Antibiotic	Cancer
Chrysomycin B is an antibiotic isolated from a strain of Streptomyces. Chrysomycin B causes DNA damage in the human lung adenocarcinoma A549 cell line and inhibits topoisomerase II. Chrysomycin B suppresses the growth of transplantable tumors in mice.

HY-172881

PKM2-IN-10	Pyruvate Kinase	Cancer
PKM2-IN-10 (Compound 16) is a PKM2 inhibitor. PKM2-IN-10 inhibits the proliferation of A549 and HCC1833 cell lines with IC₅₀ of 3.36 μM and 9.20 μM, respectively. PKM2-IN-10 exhibits antitumor activity in human non-small cell lung cancer (NSCLC) and mouse lung adenocarcinoma models. PKM2-IN-10 can be used in lung cancer research .

HY-147030

PARP1-IN-8	PARP	Cancer
PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated PARP1 inhibitor, with an IC₅₀ of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549 .

HY-144361

Antitumor agent-44	Apoptosis	Cancer
Antitumor agent-44 (Compound 5n) disrupts the mitochondrial homeostasis, induces cell cycle arrest and apoptosis in human adenocarcinoma cells. Antitumor agent-44 (Compound 5n) possesses good anti-tumor activity in a lung-cancer-cell xenograft mice model .

HY-111125

AMRI-59	Parasite Reactive Oxygen Species (ROS) Apoptosis	Infection Cancer
AMRI-59 is a potent inhibitor of PrxI used for parasitic infections. AMRI-59 can increase cellular ROS, leading to activation of signaling pathways mediated by mitochondria and apoptosis signal-regulated kinase 1, thereby leading to apoptosis in A549 human lung adenocarcinoma. AMRI-59 exhibits significant antitumor activity without apparent acute toxicity .

HY-151295

Antitumor agent-75	DNA/RNA Synthesis	Cancer
Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC₅₀ value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer .

HY-151287

KRAS inhibitor-20	Ras	Cancer
KRAS inhibitor-20 is a small molecular inhibitor of KRas ^G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRas ^G12C with the IC50 value <10 nM .

HY-N17957

Homoisopogon B	Others	Cancer
Homoisopogon B is a homoisoflavane found in the tubers of Ophiopogon japonicus. Homoisopogon B shows cytotoxic activity against cancer cells. Homoisopogon B can be used for the research of cancer, such as human lung adenocarcinoma and human melanoma .

HY-179501

PDK1-IN-5	PDK-1 Reactive Oxygen Species (ROS) Apoptosis Oxidative Phosphorylation	Cancer
PDK1-IN-5 is a selective PDK1 inhibitor. PDK1-IN-5 activaties PDH by diminishing phosphorylation level via PDK1 inhibition. PDK1-IN-5 effectively reverses the Warburg effect and shifts cellular energy metabolism from glycolysis toward oxidative phosphorylation by increased acetyl-CoA, reduced lactate, elevated mitochondrial ROS, and subsequent induction of apoptosis. PDK1-IN-5 robustly inhibits tumor growth in vivo without inducing systemic toxicity. PDK1-IN-5 can be used for lung adenocarcinoma, human non-small cell lung adenocarcinoma and gastric colorectal .

HY-P992347

DS-5573a	CD276/B7-H3	Cancer
DS-5573a is a human monoclonal antibody targeting B7-H3, with a K_d of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer .

HY-N16695

(2S,3S)-Pterosin S 14-O-glucoside	Others	Others
(2S,3S)-Pterosin S 14-O-glucoside is a sesquiterpene glycoside compound that can be isolated from the fern Pteris multifida. (2S,3S)-Pterosin S 14-O-glucoside showed no significant cytotoxicity against A549 (human lung adenocarcinoma), LOVO (colon adenocarcinoma), PANC-1 (human pancreatic cancer), and NCI-H446 (human small cell lung cancer) cell lines (IC₅₀ > 100 μM) .

HY-181657

EGFR-IN-200	EGFR TNF Receptor Interleukin Related Apoptosis	Cancer
EGFR-IN-200 is an inhibitor targeting EGFR, TNF-α, and the IL-6/GP130 complex, which potently targets human EGFR (IC₅₀=0.03 μM), TNF-α (IC₅₀=3.1 μM), and the IL-6/GP130 complex (IC₅₀=1.6 μM). EGFR-IN-200 binds to the ATP pocket of EGFR, the trimer interface of TNF-α, and the cytokine-receptor interface of IL-6/GP130, induces G₂/M cell cycle arrest, apoptosis, and antiproliferative activity. EGFR-IN-200 exhibits high gastrointestinal absorbability, low BBB permeability, and complies with the Lipinski's rule. EGFR-IN-200 can be used for the research of lung cancer and breast adenocarcinoma .

HY-174271

Antioxidant agent-21	Apoptosis	Cancer
Antioxidant agent-21 (Compound 9) is a phenolic heterocyclic compound with antioxidant and anticancer activities. Antioxidant agent-21 shows significant cytotoxicity toward human gastric adenocarcinoma (AGS) and lung cancer (A549) cells. Antioxidant agent-21 induces caspase-dependent apoptosis in cancer cells .

HY-101145

CK37	Choline Kinase p38 MAPK PI3K Akt Arp2/3 Complex PERK	Cancer
CK37 is a competitive choline kinase-α inhibitor. CK37 inhibits purified recombinant human choline kinase-α activity. CK37 suppresses MAPK and PI3K/AKT signaling, disrupts actin cytoskeletal organization. CK37 diminishs activating phosphorylations of ERK. CK37 exhibits anticancer activity against cervical cancer, melanoma, Lewis lung carcinoma, lung adenocarcinoma, breast cancer, and leukemia .

HY-181174

Antioxidant agent-22	SOD Glutathione Peroxidase Caspase Interleukin Related Bcl-2 Family Apoptosis	Cancer
Antioxidant agent-22 is a paraben derivative tetracyclic spermine cyclotriphosphazene compound. Antioxidant agent-22 exhibits antioxidant, anti-Inflammatory, and apoptotic activities. Antioxidant agent-22 significantly upregulates CAT, SOD, caspase-3 and IL-6 expression, suppresses GSH, IL-1β, and reduces BCL-2 and BAX levels. Antioxidant agent-22 can be used for the research of cancer, such as lung cancer .

HY-N17431

Cynanoside K	Others	Cancer
Cynanoside K is a pregnane glycoside isolated from Cynanchum atratum. Cynanoside K shows no activity against HL-60, KATO-III, and A549 cells .

HY-182883

KRASG12C IN-20	Ras	Cancer
KRASG12C IN-20 is an orally potent KRAS ^G12C inhibitor with an EC₅₀ of 3.9 nM. KRASG12C IN-20 covalently modifies KRAS ^G12C in its inactive GDP-bound state and locks it to block oncogenic signal transduction. KRASG12C IN-20 exhibits significant activity in lung adenocarcinoma xenograft models. KRASG12C IN-20 can be used for research related to lung adenocarcinoma .

HY-181166

EGFR-IN-194	EGFR Apoptosis	Cancer
EGFR-IN-194 is a potent EGFR tyrosine kinase inhibitor with an IC₅₀ of 54.3 nM against human EGFR. EGFR-IN-194 induces apoptosis, inhibits migration in cancer cells, selectively promotes invasion in cancer cells, and exhibits antiproliferative effects across multiple cancer cell lines. EGFR-IN-194 can be used for the research of prostate adenocarcinoma, non-small cell lung carcinoma, breast carcinoma, chronic myeloid leukemia .

HY-159803

IST-622 6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin	Endogenous Metabolite	Cancer
IST-622 (6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin) is an anti-tumor agent with significant growth inhibitory activity. IST-622 exhibits significant anti-tumor effects against a variety of mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum cell sarcoma. IST-622 was orally administered and the results showed efficacy in different tumor types. In addition, IST-622 provided significant inhibitory effects against two human tumor xenograft models: large cell lung carcinoma (Lu-116) and gastric adenocarcinoma (St-4). IST-622 also exhibited significant growth inhibitory activity against P388 leukemia in vitro, with a half inhibitory concentration (IC50) more than 20 times lower than CT .

HY-186161

Antiproliferative agent-77	Others	Cancer
Antiproliferative agent-77 is an anticancer cell proliferation agent that exerts significant antiproliferative effects on HCT116, HepG2, H1299 and MCF-7 .

HY-183582

GB1841	Galectin	Cancer
GB1841 is an orally active and selective galectin inhibitor with human galectin-1 K_d of 0.027 μM, human galectin-3 K_d of 0.14 μM, mouse galectin-1 K_d of 0.034 μM and mouse galectin-3 K_d of 1.170 μM. GB1841 can be used for the research of lung cancer .

HY-111103

CZh226	PAK LIM Kinase (LIMK) MMP	Cancer
CZh226 is a selective PAK4 inhibitor with an IC₅₀ of 0.0111 μM and a K_i of 0.009 μM. CZh226 functionally inhibits PAK4 activity and reduces the phosphorylation level of downstream signaling molecules. CZh226 inhibits the migration and invasion of tumor cells. CZh226 is applicable to lung cancer-related research .

HY-181943

SPT-IN-2	Acyltransferase	Cancer
SPT-IN-2 is an orally active serine palmitoyltransferase (SPT) inhibitor (with an IC₅₀ of 0.71 nM against human SPT2). SPT-IN-2 inhibits ceramide synthesis, suppresses cancer cell growth, and exhibits in vivo anti-tumor activity, favorable metabolic stability and cell membrane permeability in xenograft mouse models. SPT-IN-2 blocks the de novo sphingolipid synthesis pathway, significantly reducing intracellular ceramide levels and the levels of 3-ketodihydrosphingosine (3-KDS), the immediate downstream product of SPT. SPT-IN-2 can be used in research related to lung adenocarcinoma, acute promyelocytic leukemia and breast cancer .

HY-180404

SU0383	DNA/RNA Synthesis	Cancer
SU0383 is a dual MTH1 and OGG1 inhibitor with IC₅₀ values of 0.034 μM and 0.49 μM, respectively. SU0383 induces cytotoxicity in cancer cells and increases sensitivity of tumor cells to oxidative stress, and showing low toxicity in normal cells. SU0383 can be used for cancer research .

HY-182917

MMB-DTCs-1,3-diaminopropane-DTCs-MMB		Cancer
MMB-DTCs-1,3-diaminopropane-DTCs-MMB is a Cuproptosis/Ferroptosis/Apoptosis inducer, and serves as the active metabolite of DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate (HY-182918). MMB-DTCs-1,3-diaminopropane-DTCs-MMB induces mitochondrial dysfunction, promotes reactive oxygen species (ROS) production, disrupts redox homeostasis, and triggers apoptosis, ferroptosis and cuproptosis in lung cancer cells. MMB-DTCs-1,3-diaminopropane-DTCs-MMB can be used in the research of lung cancer .

HY-183788

EGFR-IN-212	EGFR Apoptosis	Cancer
EGFR-IN-212 is an EGFR inhibitor with human IC₅₀ values of 1.83 μM. EGFR-IN-212 reduces EGFR mRNA expression and induces apoptosis. EGFR-IN-212 can be used for the research of non-small cell lung carcinoma .

HY-N16806

Yunnancoronarin B	Drug Derivative	Others
Yunnancoronarin B is a natural diterpene.

Cat. No.	Product Name	Type

HY-W020955

Triphenylphosphinechlorogold

Chloro(triphenylphosphine)gold(I)

Biochemical Assay Reagents

Triphenylphosphinechlorogold (Chloro(triphenylphosphine)gold(I)) is a gold complex, Apoptosis inducer, and catalyst. Triphenylphosphinechlorogold exhibits high LOX inhibitory activity. Triphenylphosphinechlorogold induces cell cycle arrest and apoptosis. Triphenylphosphinechlorogold catalyzes the peroxidation of linoleic acid. A weak interaction exists between Triphenylphosphinechlorogold and DNA. Triphenylphosphinechlorogold displays antiproliferative activity against breast cancer cells .

HY-142997

DOSPA	Biochemical Assay Reagents
DOSPA is a cationic lipid. DOSPA can form lipid nanoparticles with DOPE (HY-112005) to serve as a carrier for nucleic acid transfection. DOSPA is applicable in research related to drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-P11845

DOTA-NT-20.3-IPBA	Radionuclide-Drug Conjugates (RDCs) Neurotensin Receptor	Cancer
DOTA-NT-20.3-IPBA is a Neurotensin receptor 1 (NTR1)-targeting albumin binder with specific high-affinity binding to NTR1. DOTA-NT-20.3-IPBA is formed by the conjugation of DOTA-NT-20.3 and IPBA. DOTA-NT-20.3-IPBA can be used for positron emission tomography (PET) imaging following labeling with [ ⁶⁸Ga]Ga .

Cat. No.	Product Name

HY-K6102

Human Lung Adenocarcinoma Organoid Kit
MCE Human Lung Adenocarcinoma Organoid Kit contains Lung Adenocarcinoma Organoid Basal Medium A, Lung Adenocarcinoma Organoid Supplement B (50×), Lung Adenocarcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human lung adenocarcinoma organoid.

Cat. No.	Product Name	Target	Research Area	Image

HY-P991739

RC148	VEGFR PD-1/PD-L1	Cancer
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .

HY-P992347

DS-5573a	CD276/B7-H3	Cancer
DS-5573a is a human monoclonal antibody targeting B7-H3, with a K_d of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer .

Cat. No.	Product Name		Classification

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909		CpG ODNs
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC₅₀ of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-142997

DOSPA		Cationic Lipids
DOSPA is a cationic lipid. DOSPA can form lipid nanoparticles with DOPE (HY-112005) to serve as a carrier for nucleic acid transfection. DOSPA is applicable in research related to drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

human lung adenocarcinoma

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products